BPC-157 Research: Mechanisms & Evidence

Summary

BPC-157 is a synthetic 15–amino-acid peptide derived from a sequence identified in human gastric juice. It is investigated for tissue repair, angiogenesis and gut barrier function. Almost all published evidence comes from rodent models; controlled human data is very limited, and long-term safety has not been characterised.

Last reviewed 2026-09-01

What it is

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV. It is a partial fragment of a larger protein isolated from gastric juice, and is stable in gastric acid — unusual for a peptide of its size.

The parent compound was characterised by a Croatian research group in the 1990s while studying protective factors in the stomach. BPC-157 emerged as the active fragment and has been the subject of several hundred rodent papers since, largely from the same research network.

It does not occur naturally as a discrete molecule; it is produced synthetically by solid-phase peptide synthesis for laboratory use.

Interest grew because rodent studies reported effects across an unusually wide range of injury models — tendon, muscle, bone, gut, nerve and vascular — which suggested a general repair-signalling mechanism rather than a tissue-specific one.

How it works

In plain terms

In animal models, BPC-157 appears to help the body form new small blood vessels at an injury site and to calm local inflammation. More blood supply to damaged tissue is the common thread across the reported effects.

Technical detail

The most consistently reported mechanism is upregulation of VEGFR2 signalling and downstream activation of the Akt–eNOS pathway, promoting angiogenesis. Rodent work also reports modulation of the nitric oxide system, interaction with the dopaminergic and serotonergic systems, effects on FAK–paxillin signalling in fibroblast migration, and increased expression of growth-hormone receptor in tendon fibroblasts. No receptor has been definitively identified as the primary binding target.

Pathways involved

VEGFR2 → Akt → eNOS (angiogenesis)
Nitric oxide system modulation
FAK–paxillin signalling in fibroblast migration
Growth-hormone receptor expression in tendon fibroblasts
Gut barrier and mucosal integrity signalling

Current research

Laboratory research

In-vitro work reports increased fibroblast migration and tubule formation in endothelial cell assays at micromolar concentrations, consistent with the proposed angiogenic mechanism.

Animal research

The rodent literature covers Achilles tendon transection, muscle crush, colitis, NSAID-induced gastric lesion, spinal cord and peripheral nerve injury models. Reported outcomes include faster functional recovery and improved histology. The concentration of publications within a small number of affiliated groups is a recognised limitation, and independent replication is thin.

Human research

Human evidence is sparse. Early-phase safety work has been described in the context of inflammatory bowel disease, but peer-reviewed, adequately powered, placebo-controlled trials in tissue repair are not available. No regulatory approval exists in any major jurisdiction.

Ongoing research

Registered trial activity remains minimal relative to the volume of preclinical publication; check the registry link below for current entries.

What is being investigated

Tendon and ligament recovery in rodent transection models
Skeletal muscle repair after crush injury
Gut barrier integrity and experimental colitis
Protection against NSAID-induced gastric lesions
Angiogenesis and local blood-vessel formation
Peripheral nerve regeneration

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

No adequately powered human efficacy trials have been published
Long-term safety and carcinogenicity data are absent — an angiogenic signal is a theoretical concern in the presence of undiagnosed tumours
A high proportion of positive findings come from a small number of affiliated laboratories, so publication and replication bias cannot be excluded
No approved pharmaceutical product exists, so material quality varies widely between sources
Effective human dose, route and pharmacokinetics are unknown

Evidence ratings

Laboratory studies

Moderate

Consistent angiogenic and migration effects in cell assays.

Animal studies

Strong

Large, broad rodent literature — but concentrated in few groups.

Human studies

Limited

No adequately powered controlled efficacy trials published.

Long-term safety

None

No chronic exposure or carcinogenicity data in humans.

Comparisons

BPC-157 vs TB-500

Two repair-associated peptides with different proposed mechanisms.

GHK-Cu

Copper-binding peptide studied in skin and wound models.

References

[1]BPC-157 — indexed literature — PubMed, 1993–present
[2]BPC-157 and angiogenesis / VEGFR2 — PubMed, 2018–present
[3]BPC-157 tendon healing models — PubMed, 2010–present
[4]Registered clinical trials mentioning BPC-157 — ClinicalTrials.gov, current
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is BPC-157?+

A synthetic 15–amino-acid peptide based on a sequence found in human gastric juice, studied mainly in rodent tissue-repair models.

Is BPC-157 FDA approved?+

No. It is not an approved medicine in the United States, the EU or the UK. In 2023 the FDA placed it on a list of substances not permitted in compounded preparations.

How does BPC-157 work?+

The best-supported proposed mechanism is promotion of angiogenesis through VEGFR2–Akt–eNOS signalling, alongside effects on the nitric oxide system and fibroblast migration.

Is BPC-157 a peptide?+

Yes — it is a pentadecapeptide, meaning a chain of fifteen amino acids.

What research exists on BPC-157?+

Several hundred rodent studies across tendon, muscle, gut, nerve and vascular injury models, plus in-vitro work. Controlled human efficacy data is not available.

Is BPC-157 the same as the protein it came from?+

No. It is a fragment of the larger Body Protection Compound found in gastric juice, and does not exist in the body as a separate molecule.

Why is BPC-157 stable in stomach acid?+

Its short sequence lacks the cleavage motifs that gastric proteases act on most readily, which is one reason oral routes have been explored in rodents.

Has BPC-157 been tested for cancer risk?+

No published long-term carcinogenicity study exists. Because the peptide promotes new blood-vessel formation in animal models, this is an open safety question rather than a demonstrated risk.

Is there independent replication of the animal findings?+

Independent replication is limited. A large share of published positive results originates from a small network of collaborating laboratories.

What is the difference between BPC-157 and its arginate salt?+

The arginate salt form is used in some studies for improved stability in solution; the active peptide sequence is the same.

Continue your research

What Is TB-500?

Thymosin beta-4 fragment studied in repair models

How GHK-Cu Works

Copper peptide and matrix remodelling

KPV research overview

Anti-inflammatory tripeptide

Peptide Research hub

All compound reviews